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Abstract
Background. In patients with steroid-dependent
nephrotic syndrome (SDNS), long-term remission
(LTR) can usually be achieved with cyclosporin A
(CSA), after alternative treatment with cytotoxic drugs
or levamisole has failed. Nevertheless, severe SDNS
recurs in some patients despite CSA maintenance
therapy. Few data are available on the clinical course
and treatment strategies in these patients.
Methods. We carried out a retrospective chart analysis
of 46 patients with SDNS treated with CSA, after
failure of cyctotoxic treatment with cyclophosphamide
(CPO). Median age at primary manifestation was 3.0
years (range 0.8–6.9) and median current age is 20.4
years (range 8.6–29.1). Patients were recruited from
three centres caring for a total of 186 patients with
steroid-sensitive nephrotic syndrome.
Results. In 14 of the 46 patients (30%; 10 male), severe
SDNS recurred again despite CSA maintenance
therapy. Seven patients relapsed beyond the age of 18
years. Nine of 14 patients received a further course of
cytotoxic treatment as ﬁrst intervention: six were
treated with chlorambucil (CLA) and three with
CPO. Four of the CLA-treated patients remained in
LTR in contrast to none after CPO. Five patients
received levamisole after CSA: only one went into
LTR, while in one other CSA could be discontinued
although further relapses occurred. One further patient
was switched to CLA after levamisole, ﬁnally inducing
LTR. Overall, six patients required two or more drugs,
and in four of these CSA maintenance ultimately had
to be restarted.
Conclusion. We conclude that SDNS can recur in
patients despite CSA maintenance therapy. Treatment
strategies for this subgroup of patients are complex
and should be standardized to optimize long-term
outcome. A subgroup of patients with childhood
SDNS continues to relapse into adulthood.
Keywords: childhood; cyclosporin A; long-term
remission; maintenance therapy; steroid-dependent
nephrotic syndrome
Introduction
The idiopathic nephrotic syndrome of childhood is
characterized by steroid responsiveness in 80–90% of
cases (steroid-sensitive nephrotic syndrome; SSNS)
[1]. Initial treatment with prednisone (60mg/m2) leads
to long-term remission in a variable proportion
of patients, but up to 40–60% develop a relapsing
course [2–4]. In particular, the development of steroid-
dependent nephrotic syndrome (SDNS; i.e. relapses
during steroid treatment or shortly after discontinua-
tion) is a major problem in up to half of these patients.
In SDNS, cyclophosphamide is frequently used as
ﬁrst alternative to steroids, although recent studies
revealed conﬂicting results concerning the long-term
remission rate [5–7]. Also, the success of levamisole, a
further alternative treatment option in SDNS, is not
predictable [8,9]. After failure of these adjunct treat-
ments, cyclosporin A (CSA) is indicated and used
frequently as a next step of intensiﬁed therapy [10–12].
With this regimen, steroid dependency can often be
controlled effectively, but CSA dependency develops
and long-term treatment is necessary.
A subgroup of patients treated with CSA develop
occasional relapses, often controlled by additional
low-dose alternate-day steroids [10]. In some patients,
however, a complicated course develops characterized
by recurrence of severe SDNS despite maintenance
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immunosuppression with CSA. There are very few
published data on this issue, with only one study
addressing this problem [13]. In this study of 52 CSA-
treated patients, CSA had to be discontinued in 16
patients for various reasons, including eight patients in
whom SDNS had recurred. In order to acknowledge
this potential problem and clinical challenge, we
retrospectively analysed our experience with 14 patients
from three large paediatric centres, in whom SDNS
recurred despite CSA maintenance treatment.
Subjects and methods
At the time of analysis, 186 patients with the idiopathic
nephrotic syndrome of childhood according to criteria of the
International Study of Kidney Diseases in Children [4] were
followed in the participating institutions. Chart review was
performed for all patients.
All patients were steroid responsive at initial presentation
and were treated according to the standards of the
Arbeitsgemeinschaft fu¨r Pa¨diatrische Nephrologie (APN)
[2,3]. Forty-six of the 186 patients (25%) ultimately received
CSA; 12 of 54 at centre 1 (Zurich), 17 of 90 at cenre 2
(Hamburg) and 17 of 42 at centre 3 (Mu¨nster). Primary
manifestation of SSNS in these patients had occurred at a
median of 3.0 years (range 0.8–6.9), with a median age of 20.4
(range 8.6–29.1) years at the time of data analysis (Table 1).
All patients had received cytotoxic treatment with cyclophos-
phamide before CSA. Ten of these were treated according to
the current protocol of the APN with 2mg/kg for 12 weeks,
and two patients had received an 8 week course plus a 4 week
course. Renal biopsy prior to administration of cyclophos-
phamide revealed minimal change nephrotic syndrome
(MCNS) in all patients. Renal biopsies were not routinely
performed during the course of CSA treatment. Patients in
whom CSA was discontinued for reasons other than SDNS
(nephrotoxicity n¼ 2, thrombocytopenia n¼ 1) were not
included in the analysis.
Treatment of relapses of SSNS was according to the APN,
i.e. administration of prednisone 60mg/m2/day until urinary
remission had been achieved for 3 days, followed by
alternate-day prednisone in a dosage of 40mg/m2 for 4
weeks [2]. All patients relapsing on CSA responded to this
standard treatment.
Steroid dependency in patients relapsing on CSA was
deﬁned according to the APN standard deﬁnition as at
least two relapses during alternate-day (40mg/m2) treatment
with prednisone or within 14 days after stopping this
treatment [5]. Long-term remission was deﬁned according
to the same APN studies as remission of treatment lasting >2
years [5].
CSA was administered at a dose of 5mg/kg/day aiming at
trough levels of 80–120 mg/l. Three patients received classical
CSA only. Nine patients were started on classical CSA but
were changed to CSA neoral after its introduction in 1995,
and two were treated only with CSA neoral. If frequent
relapses occurred on CSA, trough levels of 150 mg/l were
aimed at in centre 2 and of 200–250mg/l in centre 3.
Chlorambucil was given at a dose of 0.15mg/kg (cumulative
dose 12.6mg/kg) and cyclophosphamide at a dose of 2mg/kg
for 12 weeks, respectively. Discontinuation of CSA and
steroids was achieved within the 12 weeks of the second
cytotoxic course (n¼ 6) or within 4 weeks thereafter (n¼ 3).
Levamisole was given in a dose of 2.5mg/kg/48 h as
previously described [9]. Tapering of CSA was started after 2
months, if no relapses occurred.
Results
In 14 of the 46 patients (30%) treated with CSA, SDNS
recurred (ﬁve patients at centre 1, six patients at centre
2 and three patients at centre 3). All 14 patients had
developed at least two relapses during high-dose
alternate-day steroids (>40mg/m2/48 h), leading to
steroid toxicity with obesity, cushingoid facies and/or
striae or behavioural disturbances. At the time SDNS
recurred, patients had been treated with CSA for a
median of 5.1 years (range 1.2–11.5; Table 1).
The treatment strategies in these 14 patients are
summarized in Table 1 (individual course) and Figure 1
(according to treatment schedule). A repeated course of
cytotoxic treatment with concurrent discontinuation
of CSA was the most commonly used strategy in nine
patients. Six patients were treated with chlorambucil,
and four of these went into treatment-free long-term
remission for >2 years. One of these patients, however,
developed severe SDNS again, after being in long-term
remission for 6 years. She is currently in remission on
mycophenolate mofetil monotherapy. Three further
patients received cyclophosphamide; however, no
patient went into long-term remission; one patient
remained without relapse for 15 months but developed
infrequent relapses afterwards (four in 2 years), which
are currently controlled by intermittent steroid
therapy. The other two patients became steroid depen-
dent within 6 months after discontinuation
of cyclophosphamide.
Five patients received levamisole. Only one patient,
however, remained in long-term remission on levami-
sole monotherapy after cessation of CSA; this patient
had been treatment refractory before and had already
received two courses of cyclophosphamide. In a further
patient, CSA could be discontinued; however, relapses
(ﬁve in 2 years) persisted requiring intermittent steroid
treatment. One patient received chlorambucil after
levamisole and after occasional relapses (three in 6
years) requiring low-dose alternate-day steroids. This
medication was discontinued successfully 12 months
ago. In the other two patients, SDNS persisted and
CSA could not be stopped.
Four of the 14 patients after failure of the above
interventions were restarted on CSA maintenance: two
of them occasionally had steroid-sensitive relapses (up
to four per year) but none required (low-dose)
maintenance steroids; in one patient, CSA ultimately
was discontinued successfully and she has been in
remission off treatment for the last 12 months.
So far, seven of the 14 patients have been experi-
encing relapses beyond 18 years of age. At present, four
of these are still under paediatric care.
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Discussion
SSNS previously was regarded as a disease of child-
hood, with most patients reaching remission around
puberty [14]. We here provide further evidence that
a signiﬁcant number of patients experience a treat-
ment-refractory course despite an extended array of
immunosuppressive drugs and continue to relapse into
adulthood. The recurrence of severe SDNS despite CSA
maintenance therapy represents a special challenge.
There is limited information on this phenomenon
and, so far, only two studies from one centre [10,13]
have addressed the issue of relapses during CSA
treatment for SSNS, while one other study mainly
described patients with FSGS [15]. Hulton [10] reported
on 40 CSA-treated patients, and relapses occurred in 40
and 56% in the ﬁrst and second year, respectively,
requiring additional low-dose maintenance steroids in
40% of patients. In this study, however, some patients
had an interrupted course which might have affected
relapse rate. Short-term CSA (i.e. <1–2 years) cur-
rently is no longer recommended in general, as most
patients are cyclosporin dependent. In another series
[13] from the same institution, 16 of 53 patients were
reported in whom CSA had to be discontinued: eight of
these had developed a relapsing course with SDNS
again and ﬁve were even secondary steroid and CSA
resistant. A recent update from this centre, however,
documents a slightly improved prognosis for children
with SSNS treated with CSA although an additional
four patients ultimately needing chlorambucil are
reported [16]. The deﬁnitions of SDNS between the
studies differs, however; by using the deﬁnitions of the
APN, our patients did in fact have a severe course
relapsing on high-dose alternate-day steroids. By includ-
ing in the analysis all patients from the centres treated
with CSA, we tried to minimize a selection bias. This is
supported further by the absolute current number of
patients with SSNS, indicating that less problematic
patients are also followed in the institutions.
Concerning treatment options, in our retrospective
experience, a second course of cytotoxic treatment was
the most commonly used strategy in recurring SDNS.
Despite concerns relating to the cumulative side effects,
especially regarding gonadal toxicity and malignancy
[14,17], steroid toxicity in the patients with recurring
SDNS was severe, and repeated cytotoxic treatment
was regarded as justiﬁed in these patients, especially
as alternatives were not available. While cyclophos-
phamide is preferred for the ﬁrst course of cytotoxic
treatment, we opted for chlorambucil in six of our
patients encouraged by previous personal experience.
Fifteen patients had received chlorambucil after CSA
treatment failure, inducing a stable remission for a
median of 6 months in 11 of these, although two
patients had a further relapse [13]. Our data, although
less optimistic but with longer follow-up, underline that
chlorambucil may be preferable to cyclophosphamide
Fig. 1. Therapy of patients with recurring SDNS according to treatment schedule.
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in patients with SDNS on CSA maintenance. Four
compared with no patients had a long-term remission
of >2 years. Despite this, even after a long remission
of up to 6 years, some patients may develop relapses
again, calling for long-term follow-up of patients with
complicated SSNS. This is especially important as the
side effects of this regimen may be more severe
compared with cyclophosphamide.
Levamisole is a further option, but from previous
experience and our current data the beneﬁt in the
described subgroup with a refractory course is limited.
Individual patients, however, may beneﬁt, as did one
patient in our series, and also, in patients having
already received two courses of cytotoxic drugs, there
may be no alternative. Also discontinuation of CSA
and reversal of SDNS may be possible, even if
occasional relapses occur. The roles of other drugs
(e.g. mycophenolate mofetil or vincristine) are unclear
at present. Some patients may even remit ﬁnally after
discontinuation of immunosuppressive treatment, as
did one patient in our cohort.
Although conclusions from retrospective studies
always have to be drawn cautiously, the role of
CSA in the treatment of SSNS may be limited. Other
alternatives should be tried ﬁrst [18,19], as long-term
treatment with CSA and even CSA dependency have
to be anticipated. Treatment with high dose CSA
(aiming at trough levels beyond 200–250 mg/l) as
suggested for steroid-resistant nephrotic syndrome
could be an alternative for patients with recurring
SDNS on CSA. In centre 2, SDNS was not inﬂuenced
by increasing trough levels to 150 mg/l, and neither was
the course altered in centre 3 with even higher trough
levels. Kinetic studies (e.g. C-2 levels) might be
preferable to ﬁnd the optimal dosing regime for CSA
in SSNS and SDNS to minimize toxicity [12] and
optimize response. So far, there is no consensus on
which CSA dose or trough levels should be aimed at in
SSNS.
One further aspect is the long duration of SSNS in
some patients, although our results are more optimistic
than the recent study of Grimbert et al. [20]. In our
series, seven patients (i.e. 4% of the total population
with SSNS) compared with 102 patients born between
1970 and 1975 (i.e. 42%) of patients in that study
had documented relapses in adulthood. Together with
young age at presentation (deﬁned at <6 years at
onset), the use of immunosuppressive drugs and
especially CSA in 43% were signiﬁcant predictors of a
complicated course, underlining the importance of our
results. In fact, very young age, as in our series (median
3 years), may be an even more relevant prognostic
marker than age <6 as suggested by Grimbert, because
the majority of patients will have presented before
that. However, it should be noted that evaluation of
prognostic factors should be performed prospectively
and this was beyond the scope of our study;
importantly, genetic and immunological factors need
to be included, such as, for example, the HLA system.
Nevertheless, the documentation of relapses as well as
continued intensive treatment of a subgroup of SSNS
patients into adulthood (exempliﬁed by the present
age range of our patients) indicates that long-term
follow-up is mandatory and transfer of these patients
into adult nephrology care is necessary.
In summary, a signiﬁcant proportion of children with
SSNS develop a complicated course that is insufﬁ-
ciently controlled by CSA maintenance. Treatment of
these patients is a challenge and there is a need for more
prospective and controlled data, or at least standard-
ized consensus recommendations [18,19]. If a repeated
course of cytotoxic treatment is considered, we
currently would recommend chlorambucil instead of
cyclophosphamide until further less toxic alternatives
become available. It is now emerging that despite an
intensiﬁed array of immunological drugs, some patients
with childhood SSNS fare less well than previously
thought and need treatment and follow-up into
adulthood [21].
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